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Summary 
No disease-slowing treatments exist for Huntington’s disease (HD), but its monogenic 
inheritance makes it an appealing candidate for the development of therapeutics targeting 
pathogenic processes close to its root genetic cause.  HD is caused by CAG repeat 
expansions in the HTT gene, which encodes huntingtin protein; targeting of HTT 
transcription and the translation of its mRNA are therefore an area of intense investigation. 
‘Huntingtin-lowering’ strategies include antisense oligonucleotides (ASOs) and RNA 
interference compounds targeting mRNA; and zinc-finger transcriptional repressors (ZFTR) 
and newer CRISPR/Cas9 methods aiming to reduce transcription by targeting DNA. An 
intrathecally-delivered ASO targeting total huntingtin is now well into its first human clinical 
trial, with other ASO approaches expected to enter trials within the next 1-2 years, and 
virally-delivered RNAi and ZFTR in advanced testing in animal models. Meanwhile, recent 
advances to improve the design and delivery of targeted therapeutics are likely to improve 
their efficacy, safety, tolerability and duration of effect. 
 
Introduction 
Because all cases of Huntington’s disease (HD) are caused by the same basic mutation, it is 
an ideal candidate for the development of therapeutics targeting pathogenic processes close 
to its root genetic cause. Expansion of a CAG tract in the HTT gene results in ubiquitous 
expression of mutant huntingtin protein (mHTT), thought to be the predominant toxic 
species.1 Individuals destined to develop HD can be identified by genetic testing, so 
intervention in the long premanifest phase should postpone or prevent symptom onset.2   
HD is autosomal dominantly inherited and thought to be substantially caused by toxic gains 
of function,3,4 so reducing mHTT production should alleviate its pathogenesis. There is some 
evidence that loss of function by mHTT (i.e. haploinsufficiency) contributes to HD,5 which 
could be exacerbated by reducing HTT production – an important consideration that human 
trials must be designed to detect.  
It is a pivotal time for therapies targeting disease-associated genes and proteins. The first 
clinical success for such a therapy was recently reported: the US Food and Drug 
Administration (FDA) approved nusinersen, a lumbar intrathecally-administered antisense 
oligonucleotide (ASO) that extended survival in spinal muscular atrophy via targeted 
modulation of gene expression, increasing production of SMN2.6,7 We cannot assume 
general success from this single instance: this approach acted by restoring a missing protein 
function rather than reducing a toxic protein and SMA is typically more aggressive than HD, 
so potentially an easier disease in which to demonstrate a therapeutic effect in a relatively 
short efficacy trial. Nonetheless, the first proof that neurodegeneration can be slowed in 
humans by a targeted therapeutic modulating gene expression gives encouragement to 
similar programmes in HD. 
The term ‘gene silencing’ is sometimes used for targeted reduction in gene expression. This 
could be interpreted as complete deactivation, which is probably neither desirable nor 
attainable. We therefore prefer ‘huntingtin lowering’. The term ‘gene therapy’ is reserved for 
approaches where genetic material of living cells is modified,8 resulting in host cells 
manufacturing non-native mRNA and sometimes protein; this has special safety and 
regulatory implications. 
This review focuses on novel therapeutic strategies targeting the mHTT production pathway. 
Those designed to interact with HTT mRNA include antisense oligonucleotides (ASOs) and 
RNA interference (RNAi) compounds that accelerate degradation of the transcript; and orally 
bioavailable small molecules to reduce HTT through altering mRNA splicing. Agents that 
interact directly with HTT DNA include zinc finger transcriptional repressors (ZFTRs) and 
CRISPR/Cas9 ‘genome editing’ constructs. 
Huntingtin and the molecular pathology of HD 
The HTT gene is highly conserved,9 and its embryonic knockout is lethal,10 suggesting that 
the protein is essential for normal development. The function of wild-type huntingtin (wtHTT) 
is incompletely understood, but it is ubiquitously expressed, has many interaction partners 
and performs many likely roles including vesicular trafficking; the mediation of endocytosis, 
vesicular recycling and endosomal trafficking; coordination of cell division; transcriptional 
regulation; and metabolism.5 The toxic effects of mHTT are equally diverse, with numerous 
pathways deranged in its presence.11 Despite many attempts, no approach targeting these 
downstream pathways has succeeded,12 emphasising the difficulty of achieving clinical 
benefit in a disease with pleiotropic cellular derangements. This is perhaps one reason for 
the current emphasis on the therapies we describe here, which target the most proximal 
pathogenic events. 
Some useful functions of huntingtin may already be impaired in HD mutation carriers 
because mHTT performs them less efficiently: for example, overexpressing wtHTT 
stimulates axonal vesicular transport of brain-derived neurotrophic factor (BDNF), but mHTT 
does not, suggesting loss of huntingtin function may contribute to BDNF deficiency in patient 
striatum.13 
Lowering huntingtin could exacerbate these putative pathogenic contributions from 
haploinsufficiency. This concern needs to be balanced against the detrimental effects of the 
persistent presence of mHTT. Complete inactivation of HTT in the adult rodent brain may 
cause a progressive neurological phenotype14 but partial reduction to 50% or more in the 
adult is well-tolerated across model species, with the important caveat that follow-up times in 
these animal studies have generally been rather short.15-19 The longest primate study 
revealed no toxicity after 6 months’ partial suppression in the striatum.19 Importantly, no 
huntingtin-lowering strategy currently proposed for human use would produce complete 
knockdown. Nonetheless, it remains unknown whether long-term partial suppression of 
huntingtin in humans will prove safe, so human trials must be designed with long follow-up, 
and safety measures sensitive enough to detect toxicity from this on-target mechanism. For 
now, these concerns also favour the prioritisation of agents with shorter half-lives, that are 
reversible or that can be inactivated if problems emerge. 
The desirability of suppressing only the mutant protein (‘allele-selective’ huntingtin-lowering), 
given the greater difficulty of achieving this, is an important focus of the field. Appropriately, 
efforts to pursue allele-selective and nonselective strategies are underway. 
While a CAG-expanded HTT gene is certainly the proximal cause of HD, and mHTT is 
generally agreed to be harmful to neurons, recent years have seen growing debate about 
whether it is the sole pathogenic agent. 
Huntingtin exon 1 contains the expanded polyglutamine tract and is sufficient to cause 
pathology.20 Fragments generated from cleavage of full-length mHTT are traditionally 
thought of as the source of this toxic species, but a variant of mHTT mRNA resulting from 
incomplete splicing was recently described that encodes a short exon 1 huntingtin protein. 
This transcript is formed more avidly when the HTT gene is CAG-expanded, and has been 
found in postmortem HD patient but not control brains.21 Others have shown that huntingtin 
mRNA is subject to repeat-associated non-ATG (‘RAN’) translation, which can generate 
many unusual protein species from both sense and antisense strands, some of which may 
be toxic.22 Finally, it has been proposed that CAG-expanded HTT RNA itself may be toxic.23 
Figure 1 shows these proposed mechanisms, alongside the conventional pathway to mHTT 
and its toxic exon 1 fragment. 
The contribution of each putative alternative mechanism remains unclear, but their existence 
warrants special consideration, since the effect of each huntingtin-lowering approach on 
each pathogenic pathway will depend on precisely where the intervention targets the protein 
expression pathway. These, too, are highlighted in Figure 1. Targeting proximal events will 
be more likely to diminish these alternative mechanisms. This will need to be borne in mind, 
especially if an agent appears to have engaged with its target in a trial, but fails to ameliorate 
clinical features. 
 
Figure 1. The production of huntingtin protein, and targeted molecular therapies in development to reduce it. 
Yellow marks the pathogenic expanded CAG tract and its polyglutamine product. Therapeutic approaches are 
highlighted with pink boxes. Yellow boxes indicate the most widely accepted toxic species. Dotted arrows and 
grey boxes indicate proposed non-traditional mechanisms for the production of toxic species. The chief 
mechanisms of action of ASOs and RNAi compounds are shown at the bottom. The image of huntingtin protein is 
adapted from reference 24 under a creative commons licence (CC-BY-4.0). 
 
Targeting the RNA 
Messenger RNA is accessible in the nucleus or cytosol and, in contrast to DNA, is 
unprotected by repair machinery. Thus, reducing translation of HTT mRNA ought to be 
easier to achieve than modulating transcription or altering the gene itself. Three main 
methods exist for attempting this: ASOs, RNA interference (RNAi) compounds and small-
molecule splicing modulators (summarised in Table 1).  
Class Mechanism 
Allele 
selectivity 
Delivery Vector Sponsor Key advantages Key disadvantages Ref 
ASO 
Pre-mRNA 
degradation 
None Intrathecal None 
Ionis Single drug for all HD 
mutation carriers 
Theoretical risk from 
reducing wtHTT 
25-28 
SNP-
targeted 
Intrathecal None 
Wave Life 
Sciences 
Selective silencing of 
mutant allele 
 Several drugs required 
to treat majority of 
patients 
 SNP-targeting limits 
choice of RNA binding 
sequences, increasing 
risk of side effects 
29,30 
CAG repeat Intrathecal None Biomarin 
Selective silencing of 
mutant allele with a 
single drug for all 
mutation carriers 
Will reduce expression of 
other important CAG-
containing genes, risking 
off-target effects 
31 
RNAi 
mRNA 
degradation 
None 
Intracranial AAV2 Spark Single treatment 
provides sustained HTT 
reduction 
 Invasive delivery 
 Limited treatment 
volume 
 Cannot reverse if 
adverse events occur 
15-17 
Intracranial AAV1 Voyager 32 
Intracranial AAV5 
UniQure 
N.V. 
33,34 
Small 
molecule 
Pre-mRNA 
splicing 
Unknown Oral None 
CHDI 
Foundation 
 Highly accessible route 
of delivery 
 Readily reversible 
More difficult to achieve 
selectivity for HTT over 
other genes with non-
nucleotide therapeutic 
35 
Table 1 Current publicly-announced huntingtin-lowering programmes targeting mRNA. 
ASOs and RNAi compounds are each nucleotide-based therapeutic molecules that bind to 
mRNA selectively through Watson-Crick complementarity, triggering the cell’s RNA 
degradation machinery to dispose of the transcript. 
ASOs are synthetic single-stranded DNA molecules that principally bind pre-mRNA in the 
nucleus, targeting it for degradation by RNase H36. RNAi uses RNA-based therapeutic 
molecules – including short interfering RNA (siRNA), short hairpin RNA (shRNA) or 
microRNA (miRNA) depending on structure and sequence – that bind to mature, spliced 
cytosolic mRNA, targeting it for removal by argonaute 2, the RNAse enzyme within the RNA-
induced silencing complex (RISC).37 
Some differences between these approaches are apparent from their sites of action (Figure 
1). Acting on pre-mRNA, ASOs can target exons and introns, permitting an increased choice 
of target sequences. They are expected to reduce the production of toxic mRNA and RAN 
proteins, but whether they can prevent formation of exon 1 truncated mRNA is unclear, since 
this might be generated and released before the addition of the downstream pre-mRNA 
sequence to which the ASO binds. 
RNAi compounds act on spliced mRNA, so they could only reduce the formation of exon 1 
mRNA fragments by directly targeting a sequence within that exon, and may not prevent the 
formation of toxic RNA or RAN proteins. 
For reasons that remain obscure, single-stranded DNA diffuses well in the CNS and is taken 
up by neurons and other cells. Thus, injection of ASOs into the CSF (intraventricularly in 
mice or by lumbar intrathecal administration in larger mammals) results in fairly widespread 
delivery of drug to the brain and corresponding reductions in mRNA and protein.27 In 
contrast, double-stranded RNA has limited diffusion and cellular uptake in the CNS, so 
enhanced delivery methods or viral vectors such as adeno-associated virus (AAV) are 
needed to deliver the siRNA by injection into the brain parenchyma. Though more 
challenging, this mode of administration should permit lifelong treatment from a single dose. 
Huntingtin lowering with ASOs and RNA-based compounds has been successfully achieved 
in numerous model systems (see Keiser et al. for a detailed inventory).38 Invariably, 
reduction in HTT mRNA produces a concomitant reduction in huntingtin protein, usually 
accompanied by amelioration of pathology and improvements in neurological deficits when 
given to symptomatic animals. When given to mutation-bearing animals before disease 
manifestations begin, onset is significantly postponed.  
Despite these encouraging results, the limitations of animal models are substantial. No 
therapeutic HD animal model success has yet predicted benefit in a human trial.12 This is a 
particular concern for therapeutics administered directly into the CNS: a human brain is over 
3,000 times larger than a mouse brain and is likely vastly different in respect of diffusion 
through the cerebrospinal fluid, into the brain parenchyma and within cells. 
The use of primates can lend support to a case that a compound is capable of attaining 
broad distribution and huntingtin-lowering, but these wild-type animals, lacking mHTT, are 
incomplete models for potential toxicity and cannot inform us at all about therapeutic effect. 
Large transgenic models such as sheep and pigs and are beginning to be used39 but the 
unparalleled complexity of the human brain, and the highly variable, slowly progressive 
course of HD in patients, mean that no portfolio of animal testing will ever be a guarantee of 
success. Combining multiple small and large animal models, with an awareness of the 
particular applicability and limitations of each model, must be paired with a cautious 
approach to clinical testing in order to maximise safety and the chance of successful 
translation. 
Agents made from exogenous RNA and DNA have the potential for off-target effects. For 
instance, some synthetic oligonucleotides are recognised by toll-like receptors on immune 
cells, raising the risk of immunogenicity that may be difficult to predict from animal studies.40 
Thrombocytopenia has been observed in some trials of systemically-administered ASOs, 
and worsening peripheral neuropathy with an siRNA drug. It is not clear whether these are 
class effects.41 The brain’s immunological privilege and smaller doses needed with direct 
CNS administration may mitigate these risks in neurodegeneration: this appears to have 
been the case with nusinersen,6 but this cannot be taken for granted with new therapeutics: 
vigilance is essential. 
ASO approaches 
Several ASOs are being investigated in HD model systems, but we begin by exploring in 
detail the first targeted huntingtin-lowering compound to enter a human trial. 
IONIS-HTTRx 
In September 2015, the first patients were dosed at University College London and the 
University of British Columbia with IONIS-HTTRx, an ASO targeting human huntingtin, in a 
phase 1b/2a clinical trial.25,42 Additional sites in Germany and the UK later joined the trial.28  
The investigational compound is a synthetic 20-nucleotides sequence in which many of the 
non-bridging oxygen atoms in the phosphate backbone have been substituted for sulfur to 
transform phosphodiester linkages to phosphorothioate. Additionally, the ASO has a DNA-
like central region with 2’-O-methoxyethyl modifications at each end. This combination is 
intended to optimise CNS distribution, half-life, cellular uptake and RNAse activation (Figure 
2).26 
 Figure 2 First, second and third generation ASOs and native DNA. Each generation may contain numerous 
variations around the altered characteristic.43 HTTRx combines a phosphorothioate backbone (1st generation) with 
2’-O-MOE modification (2nd generation) and is considered a 2nd generation ASO overall.26 
After two weeks’ continuous intraventricular infusion into BACHD mice bearing a full-length 
human mutant HTT gene, huntingtin mRNA levels were reduced by up to 80% and protein 
levels by around two-thirds – reductions that persisted for 4 months. The ASO was widely 
distributed in brain across cell types including neurons and glia. Amelioration of disease 
phenotypes was seen in three different mouse models of HD, with near-complete restoration 
of motor deficits in young animals and partial improvement later in the disease in the slowly-
progressive YAC128 and BACHD models; and increased survival and reduced brain atrophy 
in the rapidly-progressive R6/2 model.27 
Curiously, the pathological and motor benefits of bolus ASO treatment outlasted the 
presence of the drug and reduction in huntingtin, suggesting that cells given a brief respite 
from mHTT can regain lost ground in the battle between damage and repair – a 
phenomenon dubbed the ‘huntingtin holiday’.44 
Lumbar intrathecal infusion of a similar ASO, complementary to primate and human HTT 
mRNA, in wild-type rhesus monkeys, produced broad ASO distribution and huntingtin 
reduction in the cortex. This infusion was safe and well tolerated.27  
The flow of CSF from lateral ventricles to spinal column to the brain’s external surface 
favours cortical more than striatal distribution, after intrathecal injection. However, ongoing 
primate pharmacokinetic/pharmacodynamics work has shown that lumbar intrathecal bolus 
ASO doses that produce ~50% cortical huntingtin reduction are associated with 15-20% 
reductions in the striatum, and were well-tolerated in these animals, providing support for 
human dose escalation.28 Wang and colleagues demonstrated that lowering mHTT 
expression in cortex or striatum each produce partial improvement in BACHD mice, but 
lowering in both regions produces a greater benefit than either alone.45 Lumbar intrathecal 
ASO injection in Yucatan pigs, whose spinal column is roughly the same length as a 
human’s, resulted in significant distribution to brain tissues.28 The striatum will probably 
receive lower doses than the cortex with intrathecal administration, but apparently attainable 
levels of lowering may be sufficient to produce clinical benefit without resorting to dual 
intrathecal/intracranial administration. Nonetheless this remains an option. 
In the current IONIS-HTTRx trial, patients with early HD receive four lumbar intrathecal bolus 
doses of drug or placebo (randomized 3:1) at monthly intervals. Several dose escalations 
have taken place within the multiple ascending dose design.25 As well as safety and 
tolerability, the trial seeks to study the pharmacokinetics of IONIS-HTTRx in the human CNS, 
and will examine target engagement biomarkers46 including the CSF mHTT concentration, 
which can be reliably quantified using a novel immunoassay.47 
Progress in other neurodegenerative diseases provides encouragement for intrathecally-
delivered ASOs. A safety trial of an ASO in superoxide-dismutase 1 (SOD1) mutation-
associated amyotrophic lateral sclerosis revealed no concerns48 and another is underway 
with a more potent ASO.49 The striking efficacy of nusinersen in SMA demonstrates disease-
modification by an ASO in a previously unalterable human neurodegenerative condition. 
Notably, post-mortem brain tissue from the trial showed ASO in neuronal and non-neuronal 
cells in cortex and brainstem, and increased SMN2 expression in multiple brain areas – the 
first evidence that lumbar intrathecal bolus ASO injection can achieve brain penetration and 
target engagement in humans.6  This result is encouraging for IONIS-HTTRx – with the 
important caveats already mentioned.  
Allele-selective ASOs 
IONIS-HTTRx is expected to reduce expression of both mutant and wild-type HTT alleles 
equally. It may be many years before we know whether lowering wtHTT is safe in humans, 
especially for long-term use in symptom-free gene carriers. Allele-selective methods for 
reducing mHTT by targeting the CAG tract or heterozygous single-nucleotide polymorphisms 
(SNPs) are under investigation. 
A long CAG tract is not unique to HTT: numerous human genes contain polyCAG 
stretches.50  Thus, an ASO or RNAi drug targeting the causative mutation is likely to 
downregulate other genes, which may produce ‘off-target’ adverse effects. Since several 
polyCAG genes encode transcription factors, these effects could be profound. Nonetheless, 
this approach appears at least feasible. An ASO targeting the mRNA equivalent of 7 CAG 
repeats produced 83% reduction in mHTT mRNA in HD patient-derived fibroblasts, with a 
lesser 43% reduction in the wild-type transcript. It also reduced the transcripts of other 
polyCAG genes including ATXN3, ATXN1 and ATN1. On the plus side, this suggests a 
polyCAG-targeting ASO could be of value in other CAG-expansion diseases; however, the 
risk from long-term reduction in all these genes, as well as apparently non-trivial reductions 
in wtHTT, limits its potential as a candidate therapeutic.51 Nonetheless this strategy was 
advanced by Datson and colleagues, who administered the ASO to R6/2 and Q175 knock-in 
mice, producing potent mHTT-lowering accompanied by clinical benefit.31 
HTT has many common single-nucleotide polymorphisms (SNPs).52 Specialist sequencing 
techniques can establish which allele a SNPs is located upon – known as ‘phasing’.53 
Thanks to haplotypes, certain SNPs frequently accompany CAG mutation; it is estimated 
that drugs targeting the commonest three SNPs would be sufficient to treat about 80% of the 
population – with the caveat that these studies were largely based on European-descended 
populations54 (HD is more prevalent in such populations than others but is present in all 
ethnicities and regions studied to date).55  Each SNP-targeting candidate must be developed 
and trialled separately – a considerable undertaking. The success of this approach depends 
on several incompletely understood factors. First, the true frequency of the SNPs in the 
population seeking treatment may differ from that in the prevalence studies. Second, the 
procedure for phasing the SNP to the mutant allele is critically important: accidental selective 
silencing of wtHTT, leaving mHTT untouched, may cause considerable harm. Third, “allele-
specificity” is relative, not absolute: the real-world selectivity of a compound for mutant over 
wild-type may be less than expected, given the close overall sequence similarity between 
the two alleles. Fourth, the need to target SNP-bearing regions dramatically reduces the 
repertoire of candidate sequences, limiting the ability to select a potent drug candidate with 
minimal off-target effects. Nonetheless, patients bearing a suitable heterozygous SNP may 
benefit from the availability of such compounds, especially if liabilities emerge from 
nonselective lowering. 
Plans to initiate parallel trials of two ASOs targeting SNP-containing regions of HTT mRNA 
have been announced.29 Potential participants will be screened for the presence of these 
SNPs within the mutant but not wild-type allele before allocation to one or other compound. 
The ASOs were selected on the basis not only of nucleotide sequence but also on the 
stereochemistry of the backbone, which may enable greater selectivity between alleles, as 
well as optimizing other aspects of pharmacokinetics.30 
Future directions 
A potentially important recent advance is the development of peptide-conjugated ASOs that, 
after intravenous injection, produced broad CNS distribution and dramatically extended 
survival in SMA mice.56 This technology warrants investigation for use in HD.  
RNA interference approaches 
No approach using RNA-based nucleotide agents has reached human trials, but many 
efforts are underway. This reflects the added delivery and distribution challenges. RNAi does 
not distribute well into brain tissue even after intraventricular administration, so stereotactic 
surgery is needed to deliver the agent directly to the brain parenchyma, probably using a 
viral vector to encourage spread and longevity. 
Virally-delivered RNA therapeutics permanently transduce CNS cells, effectively turning 
them into factories making a drug that suppresses manufacture of mHTT. Thus, these drugs 
are gene therapy. Virally-delivered gene therapy has been attempted in neurodegeneration, 
for instance a phase 2 trial in Alzheimer’s disease patients of AAV2-encapsulated nerve 
neurotrophic factor RNA. The technique was safe and well-tolerated, albeit without apparent 
clinical benefit.57 
siRNA in HD animal models 
These approaches have been successful in multiple animal systems.38 The most advanced 
published work comes from Davidson and colleagues who, having established safety, 
potency of huntingtin reduction and phenotypic benefits from AAV-delivered siRNA in 
several HD rodent models,15,16 went on to deliver a microRNA targeting the human and 
primate HTT transcript, encapsulated in an AAV2 vector, by injection into the putamen of 
wild-type rhesus macaques. A fluorescent reporter indicated successful transfection of a 
variety of cell types in a small volume of tissue (approximately 100mm3 or 100 µL) around 
the injection site, accompanied by reduction of HTT transcripts by about half. No significant 
adverse effects were detected after comprehensive histological, biochemical and clinical 
assessment. The development of dystonia in one sham-injected animal highlights the risk 
with any neurosurgical delivery technique.17 
Enhanced delivery methods 
Stiles and colleagues used convection-enhanced delivery to infuse radiolabeled ‘naked’ 
siRNA (not packaged in a viral vector) under constant pressure into the primate putamen 
continuously for several days or weeks, producing siRNA distribution and HTT suppression 
over the entire striatum.18 Other non-viral approaches have been proposed to improve CNS 
delivery and distribution of RNAi compounds. Single-stranded RNA molecules (ssRNA) 
distribute well through brain parenchyma and into cells;58 and exosomes or other ‘Trojan 
horse’ methods may eventually permit intravenous dosing.59,60 
Even with enhanced delivery methods, limited tissue distribution remains a significant 
challenge for RNA-based compounds, necessitating consideration of either multiple injection 
sites or prioritizing one region over others. Though the striatum is disproportionately affected 
in prodromal and early HD,61 whether that is because of intrinsic mHTT production or loss of 
trophic support from the cortex is debated.4 Either way, HD is undoubtedly a whole-brain 
condition. As discussed above, the cortex and striatum are each desirable targets,45 but 
whether mHTT-lowering in either is necessary or sufficient to produce clinical benefit in 
patients remains unknown. It would be preferable to act upon both – and indeed beyond, if 
possible. Any neurosurgical procedure carries risk, so early work will likely err on the side of 
caution, perhaps expanding to more ambitious approaches in time. 
Novel viral vectors 
Recent years have seen progress in viral vectors for CNS delivery. Many AAV serotypes 
exist, each of which may be combined with different cargos, enhancers and promoters. In 
2015, Stanek and colleagues reported impressive success using an RNAi agent delivered by 
AAV1 under control of a hybrid cytomegalovirus enhancer / chicken beta actin promoter, 
which when injected into primate striatum produced widespread transduction of cells in the 
cortex, thalamus and hippocampus.32 Miniarikova and colleagues demonstrated efficacy of 
an optimized AAV5-encapsulated miRNA in rodents – now being readied for clinical use.33,34 
A striking recent development was work by Deverman and colleagues, who used Cre 
recombination-based AAV targeted evolution (‘CREATE’) to develop AAV strains with novel 
capsids, selecting them for their ability to transduce neuronal tissue. One variant, AAV-
PHP.B, demonstrated 40-fold improvement efficiency over AAV9, producing widespread 
distribution and transduction in the rodent brain (Figure 2) even after intravenous 
administration. However, there was also transfection of systemic organs (liver, heart and 
muscle), raising the possibility of peripherally-mediated side-effects; and whether the virus 
transfects a sufficient diversity of CNS cell-types to produce meaningful huntingtin reduction 
remains to be seen.62  Nonetheless, this novel AAV, and the methods used to develop it, are 
of interest to the CNS gene therapy field.  
Such progress is a two-edged sword: researchers must decide whether to proceed to clinical 
trials now, using familiar but less widely-distributed vectors, or await trial-readiness of 
improved viruses and surgical techniques. Again, an incremental process will likely be 
adopted. The immunogenicity of AAVs in the human brain, especially with repeated 
administration, is also unclear. Although repeated dosing with any particular agent will not be 
needed, there is a chance that patients who volunteer for early trials may later find 
themselves unable to receive more advanced treatments because of the risk of 
immunogenicity from receiving multiple different AAV constructs.63 
‘Small molecule’ approaches  
A brain-penetrant, orally bioavailable small molecule acting on the protein manufacture 
pipeline to lower huntingtin expression is desirable. Naryshkin and colleagues used a 
screening process to identify small molecules that alter the splicing of SMN2 pre-mRNA, 
favouring the production of a functional SMN protein (a mechanism proven effective by 
nusinersen). In patient fibroblasts, these increased SMN concentration in a dose-dependent 
manner, and improved outcomes in an SMA mouse model – albeit through uncertain 
mechanisms.64 A phase 1b/2a clinical trial in SMA of the lead compound, RG7800, was 
terminated after ocular complications emerged in ongoing animal studies,65 perhaps 
highlighting an increased risk of off-target effects with protein-modulating compounds that 
lack the specificity conferred by nucleotide base-pairing. Nonetheless, a phase 1 study of a 
second compound, RG7916, was recently completed.66 Similar work is now underway to 
identify small molecule agents to lower mHTT levels.35 
Targeting the DNA 
Designing and implementing a therapeutic construct that interacts directly with DNA to 
reduce transcription of the mutant HTT gene brings fresh challenges but the potential for 
greater rewards. DNA-targeting therapeutics would be expected to ameliorate all aspects of 
HD, including those mediated by alternative splicing, non-RAN translation or any other 
mechanism we might postulate. Moreover, ‘editing’ the DNA raises the future prospect of 
germ-line treatment in living patient tissue, that could benefit future offspring as well as the 
mutation-carrier. This of course brings its own ethical issues.67 
The two DNA-targeting gene therapies currently under investigation are zinc finger proteins 
(ZFPs) and CRISPR/Cas9 (Table 2). Each uses a protein-coding sequence encapsulated in 
a viral vector, injected intracranially, that transduces cells, causing them to produce a 
functional, non-native therapeutic protein. 
Class Mechanism 
Allele 
selectivity 
Delivery Vector Sponsor Key advantages 
Key 
disadvantages 
Ref 
ZFTR 
Transcriptional 
repression 
CAG repeat Intracranial AAV 
Shire 
 Single drug for 
all HD mutation 
carriers 
 Single 
treatment to 
provide 
longterm 
treatment 
 Targeting 
transcription 
should 
ameliorate all 
pathogenic 
pathways 
 Invasive 
 Cannot be 
deactivated 
 Small treatment 
volumes 
 Risk of 
inflammation 
from non-host 
repressor 
proteins 
68 
Imperial 
College 
London 
As above, plus 
use of host-
species proteins 
reduces 
inflammatory 
effects 
Use of human 
proteins in clinical 
candidate 
compound may 
limit utility of 
animal work  
69 
CRISPR/ 
Cas9 
Genome 
editing 
SNP-targeted 
Intracranial AAV 
Harvard 
University 
 Permanent 
removal of 
genetic cause 
 Highly specific 
and targeted 
 Very early work 
in model 
systems only 
 Irreversible 
 Shares delivery 
problems with 
other virally 
delivered 
approaches 
 Ethical concerns 
re germline 
manipulation 
 Bacterial 
proteins may be 
70 
Nonselective 
HTT depletion 
by polyQ 
domain 
deletion 
Emory 
University 
75 
immunogenic 
Table 2 Current publicly-announced huntingtin-lowering programmes targeting DNA. 
 
Zinc finger proteins 
Zinc fingers are naturally-occurring structural motifs that can bind specific DNA sequences; 
they can be generated synthetically and used as DNA-targeting therapeutic compounds. 
ZFPs tooled for therapeutic use typically contain a zinc finger array specific to the DNA 
sequence of interest – one ‘finger’ per three bases – fused to a functional domain intended 
to act upon the DNA. Examples include zinc finger nucleases (ZFNs) to cleave DNA, and 
zinc finger transcription factors (ZFTRs) to modulate gene expression.71 
Though ZFNs are theoretically capable of targeted ‘genome editing’, the process is not 
currently sufficiently precise or predictable for therapeutic application in postmitotic patient 
brain cells. Unfortunately, polyCAG stretch is particularly undesirable as a target for ZFN-
mediated cleavage.69 However, zinc fingers are sufficiently reliable to contemplate clinical 
development of a therapeutic ZFTR. In order to bring the transcriptional repressor into 
proximity with the HTT promoter, the zinc finger array must bind a sequence near the 3’ end 
of the DNA sense strand. This limits the selection of target sequences and makes it difficult 
to avoid unwanted binding to other genes.  
Fortuitously, while numerous genes contain polyCAG stretches,50 this tract in HTT is closer 
to the 3’ end than in other genes, so a CAG-targeting ZFTR will have selectivity both for HTT 
over other genes, and for the mutant over the wild-type allele. Such constructs have been 
developed by two groups. Both have shown early promise in animal models, effectively 
reducing mHTT protein expression in neurons without adversely affecting the expression of 
other genes or wtHTT.68,69 To our knowledge this is the only allele-selective huntingtin-
lowering approach currently being readied for clinical use in which a single agent should 
selectively suppress mHTT long-term in all mutation carriers. 
One limitation of zinc finger therapeutics is the production of non-native proteins that can 
trigger inflammatory and immune reactions, resulting in neuronal death and limited duration 
of effect. Agustín-Pavón and colleagues combined a polyCAG-targeting ZFTR with a non-
viral promoter and a novel repressor element redesigned to be homologous to the host 
(mouse) protein. This construct produced more sustained silencing than others using non-
native protein sequences, though the mHTT level gradually rebounded over six months.72 
Such optimisations could make a difference across the lifespan of a human HD mutation-
carrier, especially as the ultimate goal is to treat once, well before symptoms begin, to 
prevent the onset of the disease. 
CRISPR/Cas9 
Clustered regularly interspaced short palindromic repeats (CRISPR) and the accompanying 
CRISPR-associated system (Cas) together form the basis of a prokaryote immune system 
that recognises and destroys foreign DNA. Cas9 nuclease can be combined with synthetic 
guide RNA (gRNA) to produce a construct that can cut DNA with high precision at any 
chosen site. The use of such CRISPR/Cas9 complexes for targeted genome editing is a 
rapidly-evolving field with huge potential for the study and treatment of diseases including 
HD.73 
The possibilities for HTT-directed CRISPR/Cas9 therapeutic strategies are legion, from 
returning alleles to harmless length by excising CAGs, to inactivating the mutant allele by 
inserting stop codons or missense mutations (perhaps, in tandem, up-regulating the wild-
type allele to replace lost huntingtin function).74 CRISPR/Cas9 in HD is at an early stage of 
investigation. It was first used to inactivate the mutant HTT allele permanently and 
selectively in patient-derived fibroblasts, using two constructs to excise a large region of HTT 
DNA resulting in near-total reduction in both RNA and mHTT protein.70 Recently the method 
was successfully tested in an HD rodent model.75 This affirms the feasibility of this approach 
but much work is needed to bring these rapidly-evolving technologies to the clinic, especially 
given recent concerns about unexpected off-target mutations with CRISPR-Cas9 gene 
editing.76  
Conclusions and future directions 
Huntington’s disease is particularly suited to advanced experimental therapeutics that target 
DNA and RNA to modulate protein expression. The first human trial is underway of an 
antisense oligonucleotide that seeks to reduce the manufacture of mutant huntingtin protein 
by targeting HTT mRNA, and future ASO trials are planned, including agents that seek to 
lower mutant huntingtin selectively. RNA-based huntingtin-lowering agents require viral 
delivery, bringing the key advantage of potential lifelong treatment from a single dose, at the 
cost of increased invasiveness, the challenge of brain penetration and risks around long-
term toxicity; nonetheless several programs are nearing clinical trials. Small molecule RNA-
targeting compounds are appealing in terms of delivery, have been shown to be attainable in 
other conditions and are being investigated for HD. Zinc-finger transcriptional repressors 
may reduce huntingtin by targeting DNA without altering it, while CRISPR-Cas9 therapeutics 
bring the promise of permanently correcting the CAG expansion mutation that causes HD – 
but these approaches share the challenges of viral delivery and bring additional liabilities of 
their own, so are further from human trials. 
This is a time of significant progress for molecular therapies targeting huntingtin expression.  
The coming years will certainly see more trials of novel agents, likely periodically boosted by 
technological improvements in CNS delivery and distribution. Early efficacy trials will focus 
on patients with early manifest disease, in whom both benefit and harm can be studied. 
Selecting suitable outcome measures and designing trials capable of identifying meaningful 
clinical benefit is an urgent focus of current work. 
If efficacy can be demonstrated in manifest HD, the next hurdle will be the leap to ‘pre-
manifest’ mutation carriers. This will need to be supported by a battery of clinical and 
imaging biomarkers that have been under concerted development for this purpose,61,77,78 
plus relatively novel biochemical markers of target engagement and biological effect.46,47,79 
Cost, availability and the infrastructural requirements for delivering invasive treatments are 
legitimate concerns, but first we must establish that disease modification is possible. 
The HD community is distinguished by its trial-readiness, with global registries of well-
characterised potential participants and strong networks of professionals and HD family 
members. While success is far from guaranteed, we are perhaps better placed than ever to 
make a meaningful impact to treat and ultimately prevent Huntington’s disease. 
 
 
Search strategy 
References for this Review were identified by searches of PubMed between 1969 and 6 
July, 2017, and references from relevant articles. The search terms "Huntington’s 
disease”[MeSH term], “gene silencing”, “huntingtin lowering”, “antisense oligonucleotide”, 
“RNA interference”, “siRNA”, “miRNA”, “zinc finger”, “CRISPR”, “Cas9” and “AAV” were 
used. There were no language restrictions. The final reference list was generated on the 
basis of relevance to the topics covered in this Review. 
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